Spyre Therapeutics is a clinical stage biotechnology company pioneering long acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases. Spyre's pipeline includes investigational extended half life antibodies targeting ?4?7, TL1A,…